In another study of melanoma resistant to a BRAF inhibitor, vemurafenib, resistant cells were more sensitive to glutaminase inhibitors than were their sensitive counterparts both in vitro and in vivo (Hernandez-Davies et al., 2015). This evidence concerns the gene BRAF and melanoma.